{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:17:53Z","timestamp":1794453473250,"version":"4.9.1"},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2025-0214_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Traditional daily recombinant human growth hormone injections can be burdensome for patients and caregivers, leading to compliance issues. Long-acting growth hormone formulations have been developed to overcome these challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0214_abs_002\">\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 7-year-old girl who developed severe lipoatrophy secondary to repeated somatrogon injections at the same anatomical site during the third month of therapy, with complete resolution after 10\u00a0weeks of treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0214_abs_003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To our knowledge, this is only the second reported case of somatrogon-induced lipoatrophy in the literature. This case also showed that lipoatrophy developing as a result of somatogron treatment is a reversible side effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2025-0214","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T09:55:42Z","timestamp":1753955742000},"page":"1098-1102","source":"Crossref","is-referenced-by-count":3,"title":["Lipoatrophy following weekly growth hormone therapy: a case report"],"prefix":"10.1515","volume":"38","author":[{"given":"Ilhan","family":"Hazer","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology , Kutahya Health Sciences University Faculty of Medicine , K\u00fctahya , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysel Nijat","family":"Bas","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology , Kutahya Health Sciences University Faculty of Medicine , K\u00fctahya , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2025111210012236355_j_jpem-2025-0214_ref_001","doi-asserted-by":"crossref","unstructured":"Deal, CL, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA, Phillip, M, et al.. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J\u00a0Clin Endocrinol Metab 2022;107:e2717\u201328. https:\/\/doi.org\/10.1210\/clinem\/dgac220.","DOI":"10.1210\/clinem\/dgac220"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_002","doi-asserted-by":"crossref","unstructured":"Yuen, KCJ, Miller, BS, Boguszewski, CL, Hoffman, AR. Usefulness and potential pitfalls of long-acting growth hormone analogs. Front Endocrinol 2021;12:637209. https:\/\/doi.org\/10.3389\/fendo.2021.637209.","DOI":"10.3389\/fendo.2021.637209"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_003","doi-asserted-by":"crossref","unstructured":"Fisher, BG, Acerini, CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr 2013;79:189\u201396. https:\/\/doi.org\/10.1159\/000350251.","DOI":"10.1159\/000350251"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_004","doi-asserted-by":"crossref","unstructured":"Chatelain, P, Malievskiy, O, Radziuk, K, Senatorova, G, Abdou, MO, Vlachopapadopoulou, E, et al.. A randomized phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency. J\u00a0Clin Endocrinol Metab 2017;102:1673\u201382. https:\/\/doi.org\/10.1210\/jc.2016-3776.","DOI":"10.1210\/jc.2016-3776"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_005","doi-asserted-by":"crossref","unstructured":"S\u00e4vendahl, L, Battelino, T, Brod, M, H\u00f8jby Rasmussen, M, Horikawa, R, Juul, RV, et al.. Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial. J\u00a0Clin Endocrinol Metab 2020;105:e1847\u201361. https:\/\/doi.org\/10.1210\/clinem\/dgz310.","DOI":"10.1210\/clinem\/dgz310"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_006","doi-asserted-by":"crossref","unstructured":"Fares, F, Ganem, S, Hajouj, T, Agai, E. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin \u03b2-subunit to the coding sequence of human erythropoietin. Endocrinology 2007;148:5081\u20137. https:\/\/doi.org\/10.1210\/en.2007-0026.","DOI":"10.1210\/en.2007-0026"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_007","doi-asserted-by":"crossref","unstructured":"Hershkovitz, O, Bar-Ilan, A, Guy, R, Felikman, Y, Moschcovich, L, Hwa, V, et al.. In vitro and in\u00a0vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone. Mol Pharm 2016;13:631\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00868.","DOI":"10.1021\/acs.molpharmaceut.5b00868"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_008","unstructured":"European Medicines Agency. CHMP safety working party\u2019s response to the PDCO regarding the use of PEGylated drug products in the paediatric population 2025. [Internet] [cited 2025 Apr 4]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientificguideline\/chmp-safety-working-partys-response-pdco-regarding-use-pegylated-drugproducts-paediatric-population_en.pdf."},{"key":"2025111210012236355_j_jpem-2025-0214_ref_009","doi-asserted-by":"crossref","unstructured":"Touraine, P, D\u2019Souza, GA, Kourides, I, Abs, R, Barclay, P, Xie, R, et al.. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol 2009;161:533\u201340. https:\/\/doi.org\/10.1530\/EJE-09-0422.","DOI":"10.1530\/EJE-09-0422"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_010","doi-asserted-by":"crossref","unstructured":"B\u00fcy\u00fckgebiz, A, Demir, A. Severe lipoatrophy in a growth hormone deficient toddler girl treated with a non-pegylated long-acting growth hormone. Children 2025;12:58. https:\/\/doi.org\/10.3390\/children12010058.","DOI":"10.3390\/children12010058"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_011","doi-asserted-by":"crossref","unstructured":"Cowell, C, Dietsch, S. Adverse events during growth hormone therapy. J\u00a0Pediatr Endocrinol Metab 1995;8:243\u201352. https:\/\/doi.org\/10.1515\/jpem.1995.8.4.243.","DOI":"10.1515\/JPEM.1995.8.4.243"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_012","doi-asserted-by":"crossref","unstructured":"Chhiba, PD, Segal, D. Lipoatrophy associated with daily growth hormone\u00a0injections. Endocrinol Diabetes Metab Case Rep 2021;21:0087. https:\/\/doi.org\/10.1530\/EDM-21-0087.","DOI":"10.1530\/EDM-21-0087"},{"key":"2025111210012236355_j_jpem-2025-0214_ref_013","unstructured":"Palese, T, Teboul, L. Growth hormone receptor knockdown sensitizes human melanoma cells to chemotherapy by attenuating expression of ABC drug efflux pumps. Endocrine 2018;59:407\u201313."},{"key":"2025111210012236355_j_jpem-2025-0214_ref_014","unstructured":"Perchard, R, Moon, R, Clayton, PE, Gevers, EF. BSPED recommendations for the use of once-weekly long-acting growth hormone therapy in children with growth hormone deficiency [online]. https:\/\/www.bsped.org.uk\/media\/2xdjdr0q\/lagh-guideline-24-04-2024.pdf [Accessed 27 June 2025]."},{"key":"2025111210012236355_j_jpem-2025-0214_ref_015","doi-asserted-by":"crossref","unstructured":"Bouloux, PM, Handelsman, DJ, Jockenh\u00f6vel, F, Nieschlag, E, Rabinovici, J, Frasa, WL, et al.. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum Reprod 2001;16:1592\u20137. https:\/\/doi.org\/10.1093\/humrep\/16.8.1592.","DOI":"10.1093\/humrep\/16.8.1592"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0214\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:02:43Z","timestamp":1762941763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0214\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,10,27]]}},"alternative-id":["10.1515\/jpem-2025-0214"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0214","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}